The Estée Lauder Companies Inc. (NYSE: EL) — A Fallen Prestige Crown at a Decade-Low Price, Mid-Rehab on the Margins It Used to Take for Granted

An independent analyst’s research note. The analysis below takes no investment recommendation and no price target. The sole exception is the Author’s Take block immediately below, which is a clearly-labeled personal opinion.

⚡ Author’s Take

This is the author’s own subjective opinion and general information, not investment advice. The analysis that follows takes no position and contains no price target.

Verdict: HOLD / accumulate-on-weakness (into the low-$70s and below). Not-a-short. Conviction: medium-low. A directional fair-value zone of ~$70–95 falls out of ~2.0–2.7x forward sales / ~18–22x a normalizing (not yet normalized) ~$3.6–4.5 of FY27–28 EPS — roughly where it trades, which is the point: the easy money was made off the $52 trough, and from $84.81 you are paying for a recovery that is real but only one-third complete.

The framing is fallen-angel / self-help turnaround, not deep-value-with-a-catalyst and not momentum. Estée Lauder is a genuine prestige-beauty franchise — 74% gross margins, two-dozen luxury brands (La Mer, Estée Lauder, Clinique, M·A·C, Jo Malone, TOM FORD, The Ordinary), and a real ~19–25% ROIC business as recently as FY2019–22 — that committed the cardinal sin of capitalizing a COVID-era China-and-travel-retail demand bubble as its permanent baseline. When Chinese consumption softened, Hainan/Korea travel-retail “resellers” normalized, and U.S. department stores kept bleeding, revenue fell from a $17.7B peak (FY22) to $14.3B (FY25), operating margin collapsed from 20% to 8%, the company posted a net loss, cut its dividend ~47% (its first cut ever), and impaired all three of its big acquisitions (TOM FORD, Too Faced, Dr.Jart+). That is a quality business that proved its moat was narrower and more channel-dependent than the bulls believed. The market has correctly de-rated it to ~2.0x sales — the 10th percentile of its own decade, P/E not meaningful (FY25 loss).

What’s changed, and why I’m not bearish: under a new CEO (Stéphane de La Faverie, since Jan 2025) the “Beauty Reimagined” plan + a doubled “PRGP” restructuring ($1.5–1.7B charges, $0.8–1.0B gross savings, ~6–7k jobs) is producing a credible inflection — FY26 is the first year of organic growth and margin expansion in four years (guide raised to ~3% organic / 10.7–11% op margin / adj EPS $2.35–2.45, +56–62%), China has gained prestige share for five straight quarters, and FY27 is guided to 12.5–13% margin. The crux is the terminal margin: at the old ~18–20% peak EL is very cheap; at a structurally lower ~13–14% — my base case, given permanent department-store erosion, a less China-dependent but lower-margin channel mix, and indie/Gen-Z competition — it is roughly fairly valued here, with the upside in time and execution, not multiple. After a ~65% bounce off the April-2025 low you are no longer buying it cheap; you are buying it fair on a recovering number. I’d want the high-$60s/low-$70s to be paid for the margin-normalization optionality with a margin of safety. The Lauder family’s ~84% voting control (on ~35% economics) caps both governance risk and the chance of an opportunistic takeout — the failed Puig talks (terminated May 2026, on which the stock rose) showed the family will not cede control cheaply.

Conviction: medium-low. Flips bullish on two-to-three more quarters of mid-single-digit organic growth with operating margin visibly marching through 13% toward the mid-teens and China/travel-retail durably positive — that would justify a re-rate toward 3x sales. Flips bearish if the margin recovery stalls in the 11–12% zone, makeup/skin-care share losses resume, or TOM FORD’s remaining ~$1.8B trademark takes another impairment — any of which says the franchise is permanently lower-quality and ~2x sales is the ceiling, not the floor.

Tag: “The beauty aristocrat in rehab — out of the ICU, not yet out of the building.”

📈 Stock Price Action — Five-Year Event Map

EL is a five-year, ~75% round-trip wipeout. From a COVID-boom all-time-high close near $346 (late 2021/early 2022) the stock fell to a $51.92 trough (April 2025) — an ~85% peak-to-trough drawdown, one of the most violent de-ratings in mega-cap consumer staples this cycle — before a sharp recovery to ~$106 (January 2026), a pullback to ~$70 (April 2026), and $84.81 as of 2026-06-18. The 52-week range is $66.97–$118.78; the stock sits ~75% below its all-time high and ~29% below its 52-week high. This is the price context the rest of the memo assumes: not a stable compounder, but a fallen franchise whose valuation already embeds a severe — possibly permanent — reset.

Cycle narrative. (1) EL was a prime COVID beneficiary — prestige skincare and fragrance boomed and Chinese travel-retail demand exploded, lifting FY21 EPS to a record $7.79 and the multiple to ~7x sales. (2) China’s 2022 lockdowns and the travel-retail air-pocket cratered both volume and the multiple. (3) A brief 2023 “reopening” rally faded fast (4) as it became clear the Hainan boom had been inflated by grey-market resellers whose inventory then had to clear, while U.S. department-store traffic kept declining and EL lost makeup share to indie/Gen-Z brands. (5) The capitulation signals came in late 2024 — the first dividend cut in company history, withdrawn long-term targets, and a CEO change — driving the stock into the $60s; (6) the April-2025 tariff shock and the FY25 operating loss/impairments marked the $52 bottom. (7) From there a doubling off the low priced in the early, real evidence that Beauty Reimagined was working (China share gains, sequential margin beats). (8) The 2026 chop reflects a maturing turnaround meeting macro/tariff noise; the Puig episode — a confirmed ~$40bn merger discussion in March that was called off in May, on which EL shares rose — underscored that investors prize the standalone self-help story (and family control) over a transformative, potentially dilutive combination. (Price moves: Fact, from five-year public price history. Attributed drivers: Interpretation, cross-referenced to filings, dividend-cut/CEO 8-Ks, earnings prints, and news.)

1. Executive Summary

The Estée Lauder Companies is the world’s second-largest pure prestige-beauty company (behind L’Oréal’s luxury division), a ~$14.8B-revenue, family-controlled portfolio of 20-plus luxury and prestige brands across skin care, makeup, fragrance and hair care, sold in ~150 countries primarily through a wholesale model (department stores, specialty-multi, travel retail) plus a growing direct-to-consumer and online channel. For most of the past two decades it was a high-quality compounder: ~74–77% gross margins, mid-to-high-teens operating margins, and ROIC in the high-teens to mid-20s — the financial signature of genuine brand-based pricing power.

That signature broke. EL bet its planning on a COVID-era demand bubble in two concentrated channels — Mainland China and Asian travel retail (Hainan, Korea) — and when both reset, the model came apart. Revenue fell from a $17.74B peak (FY22) to $14.33B (FY25), operating margin from ~20% to 8%, and the company swung to a net loss of $1.13B (EPS −$3.15) on ~$1.29B of brand impairments (TOM FORD, Too Faced, Dr.Jart+) — confirming its three signature acquisitions were overpaid. ROIC fell from ~19% (FY22) to below the cost of capital. Management cut the dividend ~47% (the first reduction in modern company history), halted buybacks, and doubled the “PRGP” restructuring to $1.5–1.7B of charges targeting $0.8–1.0B of gross savings and ~6,000–7,000 job cuts.

FY2026 is the inflection year. Under new CEO Stéphane de La Faverie (a 14-year insider, CEO since January 2025) the “Beauty Reimagined” strategy is delivering the first year of organic sales growth and operating-margin expansion in four years: guidance was raised to ~3% organic growth, ~10.7–11% operating margin, and adjusted EPS of $2.35–2.45 (+56–62%); a preliminary FY27 view targets 12.5–13% margin. China has outperformed prestige beauty for five straight quarters, Hainan travel retail has re-accelerated (+30% retail in the latest quarter), and fragrance is growing double digits.

The investment question is not whether EL is a good business — at the gross-margin and brand level it plainly is — but what its normalized margin and growth are, now that department stores are in secular decline, travel retail is structurally lower-margin, China is contested by local “C-beauty,” and indie/Gen-Z brands have fractured the makeup category. The market’s answer, embedded in ~2.0x sales (10th percentile of EL’s own decade) and a not-meaningful P/E, is “a permanently lower-quality, low-double-digit-margin business.” The bull case is that Beauty Reimagined restores mid-teens-plus margins on a re-diversified channel base, re-rating the stock toward 3x sales. The bear case is that the franchise is structurally impaired and ~2x sales is fair. The truth is probably in between — which, after a ~65% bounce off the trough, makes the risk/reward at $84.81 balanced rather than compelling. The Lauder family’s ~84% voting control (on ~35% economics) is both a governance constraint and a takeout-floor; the May-2026 collapse of merger talks with Puig confirmed the family’s preference for the standalone path.

2. Business Overview

What it does. Estée Lauder manufactures and markets prestige and luxury beauty products in four categories: Skin Care (~49% of FY25 sales; the profit engine — Estée Lauder, La Mer, Clinique, The Ordinary/DECIEM, Dr.Jart+, Origins, Darphin), Makeup (~29% — M·A·C, Clinique, Estée Lauder, Bobbi Brown, Too Faced, Smashbox), Fragrance (~17% — Jo Malone London, TOM FORD, Le Labo, Editions de Parfums Frédéric Malle, KILIAN PARIS, AERIN, BALMAIN Beauty), and Hair Care (~4% — Aveda, Bumble and bumble). It is a “steward of over 20 luxury and prestige brands” sold in ~150 countries.

How it makes money. EL is primarily a wholesaler to third-party retailers — department stores, duty-free/travel-retail operators, specialty-multi chains (Sephora, Ulta), perfumeries, pharmacies and salons — supplemented by a direct-to-consumer business: ~1,600 freestanding stores (mostly M·A·C, Jo Malone, Le Labo), brand.com sites in ~50 countries, and third-party online platforms (Amazon Premium Beauty, Tmall, Douyin, TikTok Shop, Coupang). Management states online is ~one-third of global sales and DTC over 30%; in the U.S., online is approaching ~40%. No precise channel-mix percentages are disclosed (an Open Question). The economics are classic prestige beauty: ~74% gross margin reflecting brand pricing power and premium positioning, against heavy advertising/sampling/merchandising spend (embedded in SG&A; historically ~25%+ of sales, not separately broken out).

Revenue segmentation. EL reports by product category (the four above) and by geography. Through FY2025 the geographies were the Americas, EMEA (which contained Asian travel retail), and Asia/Pacific. Beginning FY2026 EL re-segmented into four regions — Americas; EUKEM (Europe/UK + Emerging Markets, ex-travel-retail); Asia/Pacific (now including global travel retail); and Mainland China as a standalone reported region — a genuine transparency improvement that, for the first time, isolates the two swing factors (China and travel retail) that drove the boom and bust.

Recurring vs. non-recurring. Beauty is a high-repeat consumable — skin care and makeup are replenishment-driven, fragrance more discretionary/gifting-led. There is no subscription/contract recurring revenue, but the consumable, habitual nature of the core categories gives the revenue base reasonable underlying stability at the consumer level. The volatility EL has suffered is channel- and geography-driven (travel-retail destocking, China sentiment, department-store traffic) far more than end-consumer demand collapse — an important distinction for the recovery thesis.

Verdict. A high-gross-margin, globally diversified, brand-portfolio consumer business with genuine premium positioning — but one whose reported results are highly sensitive to a few concentrated, volatile distribution channels, which is the root of the past three years’ damage.

3. Industry Dynamics

Structure and profit pools. Global beauty and personal care is a large (~$500B+ retail), structurally growing market (low-to-mid-single-digit secular volume growth plus premiumization), of which prestige beauty — EL’s arena — has historically grown faster than mass and carried far richer margins. The category has attractive long-run characteristics: habitual repeat purchase, emotional/aspirational brand equity, premium pricing, low capital intensity, and a long demographic tailwind (management cites ~500M new middle-class consumers entering the category globally by 2030, plus a widening age range of beauty consumers). On a Greenwald lens, prestige beauty is a genuinely good industry at the category level — brand-based intangibles and consumer habit are real demand-side advantages.

But the competitive intensity has risen materially, and this is the crux of EL’s structural challenge:

• Channel disruption. The historical prestige-beauty distribution backbone — department stores — is in secular decline in EL’s core Western markets (the 10-K explicitly flags “a longer-term decline in retail traffic in our department store customers”). The growth has migrated to specialty-multi (Sephora/Ulta), pure-play online (Amazon, TikTok Shop, Tmall/Douyin), and DTC — channels where EL was historically under-indexed relative to L’Oréal and where shelf space is contested by hundreds of brands.
• Indie / Gen-Z fragmentation. Social-media-native and influencer-founded brands (Rare Beauty, e.l.f. Beauty, Charlotte Tilbury, Glossier, Fenty, Hailey Bieber’s Rhode, etc.) have taken outsized share of makeup in particular, where EL has bled share for years. The barriers to launching a credible beauty brand have fallen (contract manufacturing + social distribution), compressing the incumbency advantage in the most fashion-driven category.
• China “C-beauty.” Local Chinese brands (Proya, Florasis, etc.) have gained domestic share with national-pride positioning and faster digital execution, pressuring Western prestige in EL’s single most important growth market.
• Travel-retail normalization. The Hainan/Korea duty-free boom that inflated EL’s FY21–22 was partly a grey-market reseller phenomenon; its normalization (plus retailers shifting to “more profitable duty-free business models” with lower replenishment) structurally lowered both the volume and the margin of a channel EL had become over-dependent on.

Regulation. Relatively light vs. other staples — product-safety/ingredient regulation (FDA/EU), cross-border tariffs (a live FY26 headwind, partly offset within PRGP), and litigation tails (the $159M FY25 cosmetic-talc settlement). Not rate- or reimbursement-regulated.

Marathon capital-cycle read. The prestige-beauty supply side saw a capital-and-capacity influx during the COVID boom — incumbents and PE money funding indie brands, new entrants, and aggressive travel-retail/China buildout — exactly the conditions Marathon warns precede mean-reverting returns. EL’s own ROIC collapse from ~19% to sub-WACC is textbook: high returns attracted capital (its own M&A at peak multiples included), and returns reverted. The capital cycle is now arguably turning favorable — indie-brand funding has cooled, EL and peers are cutting capacity/costs, and the weakest channels are rationalizing — which supports the recovery thesis at the industry level.

Verdict: a structurally good category that has become a more competitive industry. The long-run demand tailwinds (premiumization, emerging-market middle class, category resilience) are real, but the durable-incumbent advantages have weakened — channel power has shifted to retailers and platforms, and brand barriers have fallen in makeup. Net: a good industry, but no longer the near-oligopoly that justified EL’s old multiple.

4. Competitive Position

The moat — real but narrower than believed. In Greenwald’s taxonomy EL’s advantage is demand-side intangibles (brand) plus, secondarily, scale economies in advertising, R&D and distribution. The brand advantage is genuine and shows up in the 74% gross margin and in the pricing power of the crown jewels — La Mer (ultra-luxury skin care, repeatedly cited as the single largest contributor to organic growth), Estée Lauder (the namesake skin-care/makeup brand), Clinique, M·A·C, and the luxury-fragrance stable (Jo Malone, TOM FORD, Le Labo). These are brands with decades of equity, prestige positioning and customer affinity that a new entrant cannot replicate quickly. That is a real moat.

But the moat failed the durability test in three ways:

1. It is brand-specific, not franchise-wide, and it does not confer customer captivity to EL the company. A consumer loyal to La Mer is captive to La Mer, not to Estée Lauder Companies; there is no cross-brand lock-in, switching cost, or network effect binding the portfolio together. When individual brands lose relevance (makeup, Dr.Jart+, Too Faced), the portfolio bleeds — which is exactly what happened.
2. It is channel-dependent. EL’s distribution model relied on department stores and travel retail — channels EL does not control and that are in structural decline or were structurally inflated. The moat did not protect EL when its distribution was disrupted, revealing the advantage was partly a legacy-channel position, not a pure brand fortress.
3. The acquisition strategy destroyed value, not built moat. EL impaired all three of its signature deals — TOM FORD ($773M trademark impairment in FY25, on a 2023 purchase; $1.8B trademark still on the books and at further risk), Too Faced ($138M, goodwill written to zero; bought 2016 for ~$1.45B), and Dr.Jart+ ($375M in FY25 + $471M in FY24, goodwill to zero; bought 2019). Buying brands at peak multiples and writing them down is the opposite of widening a moat.

Direct comparison vs. key competitors. EL’s most relevant peer is L’Oréal — larger, more diversified across mass and prestige, far stronger in the channels and geographies where growth has migrated (digital, derma-cosmetics via CeraVe/La Roche-Posay, China actives), and a more disciplined acquirer. L’Oréal has consistently out-executed EL through this cycle. Coty (EL’s closest factor twin) is a more fragrance-/mass-skewed, more levered, weaker-brand competitor — EL is a higher-quality asset than Coty. Versus e.l.f., Rare Beauty, Charlotte Tilbury and the indie cohort, EL is the incumbent losing share in makeup but holds the high ground in luxury skin care and fragrance, where indies have less traction. The encouraging recent data point: EL claims to be gaining U.S. prestige volume share across all four categories and China prestige share for five straight quarters — early evidence the brand equity, properly activated and re-channeled (Amazon, Sephora for M·A·C, TikTok Shop), can re-engage.

Verdict: a real but narrower, brand-specific moat that proved channel-dependent and was not widened by M&A. EL has durable pricing power in its luxury skin-care and fragrance crown jewels, but it does not have a wide, franchise-level competitive advantage, and it has demonstrably lost ground in makeup and in the fastest-growing channels. This is a “collection of good brands” more than an unassailable franchise — which is precisely why the market no longer pays a near-monopoly multiple.

5. Growth History and Forward Opportunities

Historical revenue (fiscal years ending June 30): $14.86B (FY19) → $14.29B (FY20, COVID dip) → $16.22B (FY21, +13%) → $17.74B (FY22, +9%, PEAK) → $15.91B (FY23, −10%) → $15.61B (FY24, −2%) → $14.33B (FY25, −8%). Revenue round-tripped back below FY19 — a lost half-decade at the top line. The FY21–22 surge was disproportionately Asia travel retail and China; the FY23–25 collapse was the unwind of that same channel plus U.S. department-store erosion and makeup share loss.

Category trajectory (FY25 vs FY24): Skin Care −12% (to $6.96B), Makeup −6% ($4.21B), Fragrance +0.2% ($2.49B, the relative bright spot), Hair Care −10% ($0.57B). Fragrance has been the portfolio’s resilient category; skin care (the profit engine) took the hardest demand hit because it is most China/travel-retail-exposed.

Geographic trajectory (FY25): Americas −4%, EMEA (incl. travel retail) −13%, Asia/Pacific −7%. The Asia/Pacific operating-income collapse is the headline — from +$824M (FY23) to +$9M (FY25) — the China-and-travel-retail profit pool essentially evaporated.

The FY26 inflection (the forward story). After four years of decline, FY26 returns to growth: 9-months-FY26 organic +~2–3%, with 3 of 4 regions growing, led by high-single-digit Mainland China retail and double-digit priority-emerging-market growth, and the Americas “stabilized.” Category-wise, fragrance is up double digits (outperforming the industry), skin care is growing low single digits, makeup’s decline is slowing, and hair care has stabilized. Management raised FY26 to ~3% organic growth and guides FY27 to 3–5%.

Forward opportunities (the bull’s growth levers):

• China + travel-retail recovery: five consecutive quarters of China prestige share gains; Hainan retail +30%; travel retail back to low-single-digit growth and guided to mid-single-digit improvement. If China consumption and travel normalize upward from a low base, the operating leverage is significant (Asia/Pac op income has ~$800M of recovery headroom vs FY23).
• Channel re-platforming: M·A·C’s entry into U.S. Sephora (#1 makeup brand in launch stores its first month); 12 brands now on U.S. Amazon Premium Beauty; expansion on TikTok Shop, Tmall, Douyin, Coupang. EL was under-indexed online/specialty-multi and is closing that gap — a structural growth source if executed.
• Fragrance momentum: the fastest-growing, most-resilient category, with successful luxury launches (Le Labo, TOM FORD, KILIAN, BALMAIN Beauty) and a “fragrance wardrobe” cultural tailwind.
• Emerging markets + tuck-ins: India (Forest Essentials — buying out the rest; Bobbi Brown growth), 111Skin minority stake (pre/post-procedure), longevity/skin-health positioning.
• Innovation pipeline + AI-enabled operating model (Accenture/Shopify/WPP partnerships) as a growth-and-efficiency lever.

Verdict: historically low-quality growth (channel-and-geography-inflated, then destroyed), now at a genuine but early inflection. The FY21–22 “growth” was a bubble that reversed; crediting management with durable growth requires several more quarters of evidence. The FY26 turn is real and broad-based (categories, regions, channels all improving), which is encouraging, but the guided 3–5% organic growth is recovery off a deep base, not a re-established secular growth algorithm. Quality of forward growth is improving; durability is not yet proven.

6. Financial Quality

Margins and the operating-leverage story. Gross margin has been remarkably stable through the crisis (~74–77%), confirming the pricing power survived — the damage was all operating deleverage and impairments, not gross-margin erosion. Operating margin: 17.6% (FY19) → 20.0% (FY22 peak) → 11.1% (FY23) → 10.0% (FY24) → 8.0% (FY25). The collapse reflects fixed-cost deleverage on falling volume plus elevated A&P/inventory write-downs, not a structural gross-margin problem — which is why the PRGP cost-out + volume recovery can restore margin quickly (FY26 guide 10.7–11%, FY27 12.5–13%, Q3-FY26 already printed 15% on an adjusted basis). This is the single most important financial fact in the bull case: the margin is recoverable because the gross margin never broke.

Earnings and ROIC. Net income: $1.79B (FY19) → $2.87B (FY21) → $2.39B (FY22) → $1.01B (FY23) → $0.39B (FY24) → −$1.13B (FY25). The FY25 loss is driven by ~$1.29B of impairments plus $481M of restructuring charges plus the $159M talc settlement — i.e., the cash earnings power is materially better than the GAAP loss implies. ROIC tells the quality story cleanly: ~25% (FY19), ~18–19% (FY21–22), 8.2% (FY23), 5.1% (FY24), negative (FY25). EL went from a clearly moaty (high-teens/20s ROIC) business to a sub-cost-of-capital one in three years. The recovery thesis is, in effect, a bet that ROIC normalizes back toward the low-to-mid-teens (not necessarily the old 20%).

Cash flow — better than the income statement. Operating cash flow was $1.27B in FY25 (vs net loss of −$1.13B), and 9-months-FY26 OCF was $1.2B vs $671M a year earlier — a meaningful inflection. Capex is being cut (FY26 9-mo capex $306M, −23%), so free cash flow is recovering. FY25 FCF (~OCF minus ~$1B capex) was modestly positive; the cash engine never stopped, which is what funded the (reduced) dividend and debt paydown through the trough. Quality-of-earnings is reasonable: the gap between GAAP loss and positive OCF is explained by non-cash impairments and deferred-tax movements, not aggressive accruals — a clean, if ugly, set of numbers.

Balance sheet — adequate but not a fortress, and tangibly thin. Cash $2.92B (June 2025); total debt ~$9.3B (LT borrowings $7.31B + ~$2.15B capital leases); net debt ~$4.4B (~2.2x depressed FY25 EBITDA of ~$2.0B; closer to ~1.8x on normalizing EBITDA). An undrawn $3.5B revolver and CP program provide ample liquidity; no covenant or maturity-wall issues; ratings A−/A3, both on negative outlook. The notable flag: tangible equity is deeply negative — goodwill ($2.14B) + other intangibles ($3.76B) = $5.9B against total equity of only $3.87B, so tangible book value is roughly −$2B (TCE ratio ~−14.5%). Book equity itself shrank from $5.31B (FY24) to $3.87B (FY25) on the loss and dividends. This is not a solvency concern (the brands have real off-balance-sheet value and the cash flow is positive), but it removes any “asset-value floor” — the equity is worth the franchise’s earning power, nothing more, and a further large impairment (e.g., TOM FORD’s $1.8B residual) would erode book equity meaningfully.

Dilution/SBC. Share count is flat-to-down (~360M, dual-class); SBC ~$304M/year (~2% of sales) is moderate and not a major dilution driver. Buybacks have been halted to preserve cash (FY22 $2.31B → ~$35M in FY24–25).

Verdict: economics that genuinely improve with scale (the gross-margin proof) but that were destroyed by volume deleverage, with a balance sheet that is adequate-but-tangibly-thin and on negative ratings watch. The financial quality is “good business, trough earnings, recovering cash flow, no balance-sheet crisis” — the numbers support a recovery thesis, but the negative tangible equity and negative-outlook ratings remove any margin of safety from the asset side.

7. Capital Allocation

The historical record is mixed-to-poor, dominated by ill-timed M&A. EL’s defining capital-allocation decisions of the last decade were its prestige-brand acquisitions, and the scorecard is damning: TOM FORD (2023, ~$2.3B), Too Faced (2016, ~$1.45B), and Dr.Jart+ (2019, ~$1.7B for the remaining stake) have all been impaired — Too Faced and Dr.Jart+ goodwill written to zero, TOM FORD’s trademark already cut $773M with $1.8B still at risk. Buying brands at peak multiples near the top of the cycle, then writing them down, is the clearest possible evidence of capital misallocation. The acquisitions added revenue and impairments, not durable per-share value.

Buybacks were pro-cyclical. EL repurchased heavily near the highs (FY22 ~$2.3B with the stock at $250–340) and stopped at the lows (FY24–25 ~$35M with the stock at $52–90) — the textbook wrong-way pattern, buying high and not buying low. To management’s credit, halting buybacks in the trough was the correct liquidity decision given the loss and dividend, even if the prior buying was poorly timed.

The dividend cut was the right call, made late. The ~47% quarterly dividend cut ($0.66 → $0.35, from the Oct-2024 declaration) — the first reduction in the company’s modern history — was a necessary capital-preservation move given the operating loss and the desire to fund PRGP and protect the credit rating. It was the correct decision, but its necessity is itself an indictment of how stretched the prior payout had become against collapsing earnings.

PRGP is disciplined cost surgery. The restructuring ($1.5–1.7B charges for $0.8–1.0B of recurring gross savings, ~6,000–7,000 positions) is appropriately aggressive and is already showing up in margin. Cutting unproductive department-store doors and beauty-advisor headcount while reinvesting in consumer-facing/digital is the right reallocation. Current capital allocation (cash to deleveraging, PRGP, reinvestment; minimal buyback; reduced dividend; small tuck-ins like Forest Essentials/111Skin) is sensible and per-share-rational — a clear improvement over the peak-cycle M&A-and-buyback posture.

Incentive alignment — above-average on metrics, constrained by family control. Unlike many of the names in this coverage, EL’s comp plan does use ROIC (20% of both the annual bonus and the long-term PSUs) and a per-share EPS metric (20–40%) alongside net sales and operating margin — a genuinely returns-and-per-share-aligned design that explicitly penalizes the kind of size-for-size’s-sake growth that got the company into trouble. The gaps: no relative-TSR metric and no explicit free-cash-flow metric, and the FY26 CEO grant tilted to 60% options/40% RSU (no PSUs in that tranche), which is more upside-levered than ideal. CEO de La Faverie’s FY25 comp was $21.8M (up from $17.9M on his promotion reset) — rich for a loss-making year, though largely equity that only pays on recovery. Say-on-pay passed at ~93%.

Insider tape — zero conviction. Across a ~50-filing Form 4 sample (April 2025–June 2026), there were no open-market purchases (code P) by anyone — not the CEO, not the CFO, not a single Lauder — despite the deepest drawdown in company history. Activity was routine grants/option-exercises/tax-withholding plus large estate-driven family-trust sales following Leonard Lauder’s June 2025 death (e.g., the Leonard A. Lauder 2013 Revocable Trust sold ~2.79M shares at ~$89.70, ~$250M). The estate sales are not a directional signal, but the absence of any insider buying at $52–70 is a genuine non-endorsement — if management and the family believed the stock was deeply undervalued in the trough, the tape doesn’t show them acting on it.

Verdict: a poor historical record (peak M&A, pro-cyclical buybacks) now in the hands of a more disciplined regime (cost surgery, dividend reset, ROIC-linked comp, tuck-ins only). The forward capital allocation is materially better than the backward, but the zero-conviction insider tape and the family-control overhang temper any positive read.

8. Changes and Headwinds — Last Two Years

Leadership and governance. The defining change is the CEO transition: Fabrizio Freda (CEO ~16 years) handed off to Stéphane de La Faverie on January 1, 2025 (Freda staying as Special Advisor through June 2026). A new CFO, Akhil Shrivastava, is also in place. On the family/board: Leonard A. Lauder (Chairman Emeritus) passed away in June 2025; William P. Lauder is non-executive Chair (since Nov 2024); Ronald Lauder left the board (Jan 2025, replaced by Eric Zinterhofer); Jane Lauder moved from executive to non-management director. A generational transition is underway at both the management and family-ownership levels.

Strategy reset. “Beauty Reimagined” (launched Feb 2025) reorganized the company into “One ELC” (fewer layers, regional/brand/functional integration), re-segmented reporting (isolating China and travel retail), expanded the PRGP restructuring, and pivoted capital and headcount from declining department-store doors toward online/specialty-multi/DTC. Major operating-model partnerships were signed (Accenture for enterprise services, Shopify for DTC, WPP for media).

The Puig episode. In March 2026 EL confirmed discussions with Puig (the Spanish luxury-beauty group, owner of Charlotte Tilbury, Rabanne, Jean Paul Gaultier, Carolina Herrera) about a potential ~$40bn business combination; the talks were terminated May 21, 2026, and EL shares rose on the news. Interpretation: the market preferred the standalone self-help story and was wary of dilution/integration risk and the governance complexity of combining two founder-controlled houses — and the Lauder family signaled it would not cede control. A notable “dog that didn’t bark.”

Operating headwinds still live. (1) Tariffs — a FY26 gross-margin headwind, partly offset within PRGP. (2) Middle East conflict — disrupted EUKEM shipments (~1–2 points of growth/quarter, ~$0.07 EPS in FY26). (3) U.S. department-store/retailer bankruptcies — cost ~2 points of Americas growth in the latest quarter. (4) Negative ratings outlook at both agencies. (5) China macro — still “subdued” at the consumer level even as EL gains share.

Verdict: the changes strengthen the thesis on balance — new leadership executing a coherent, cost-disciplined, channel-modernizing turnaround that is producing measurable results, and a strategic-clarity signal (rejecting the Puig combination) — but against persistent macro/geopolitical/channel headwinds that keep the recovery non-linear and the visibility low.

9. Risk Analysis (Risk Matrix)

Overall: the dominant risks are thesis risks (does the margin and growth recovery prove durable?) rather than survival risks. The realistic bad case is a de-rating/value-trap — the stock stuck near ~2x sales because the recovery plateaus — not impairment of the equity. Total-loss risk is low.

10. Valuation Discussion (Embedded Expectations)

Where it trades. At $84.81 (2026-06-18): ~362M shares → market cap ~$30.7B; net debt ~$4.4B → EV ~$35B. On TTM/forward figures: EV/sales ~2.3–2.4x, EV/EBITDA ~13–14x (on depressed EBITDA), and a not-meaningful trailing P/E (FY25 loss). On forward earnings: FY26 adjusted EPS guide $2.35–2.45 → ~35x FY26 adj EPS; FY27 preliminary margin (12.5–13%) implies roughly $3.6–4.0 of EPS → ~21–24x FY27.

Own-history percentiles (the key valuation datum). On EL’s own ~decade range, price/sales sits at the ~10th percentile and the composite valuation at the ~16th percentile (P/B ~21st; P/E not meaningful). EL traded at 4–7x sales in FY2019–2023; it is now at ~2.0x. This is the cheapest the stock has been on sales in a decade — the market is explicitly pricing a permanently lower-margin, lower-growth franchise. The valuation is not expensive; the question is whether ~2x sales is a floor (margin recovers, re-rate) or fair value (margin is structurally lower).

Embedded expectations — what the current price implies. At ~2.0x sales / ~21–24x FY27 EPS, the market is underwriting roughly: low-single-digit organic growth, operating margin recovering to ~12–13% (consistent with guidance) and then plateauing there, and ROIC normalizing to the low teens — i.e., a permanently lower-quality EL than the FY19–22 business. The price does not embed a return to high-teens/20% margins or a re-rating back toward the historical 4–5x sales. In embedded-expectations terms, the market is paying for the guided recovery and essentially nothing beyond it.

Scenario analysis (illustrative, directional — not a price target):

• Bear (~30%): Margin recovery stalls at ~11–12%; China/travel-retail relapse; makeup share loss resumes; another impairment. Revenue stagnates ~$14–15B, EPS settles ~$2.50–3.00, multiple de-rates toward ~1.7–2.0x sales / ~15–17x EPS → a value-trap in the ~$45–60 zone. The equity is range-bound-to-lower; the dividend holds; no impairment of the business, just the multiple and the earnings power.

• Base (~50%): Beauty Reimagined roughly delivers — FY27 margin 12.5–13%, organic growth 3–5%, EPS ~$3.6–4.2 by FY27–28, multiple holds ~2.0–2.5x sales / ~20–22x EPS → roughly the high-$70s to mid-$90s, i.e., around spot. Total return comes from earnings growth (margin × modest revenue), not multiple expansion. Fairly valued; you earn the recovery, not a re-rating.

• Bull (~20%): China + travel retail durably re-accelerate, channel re-platforming compounds, and margin marches through the mid-teens toward ~16–18% on ~$16B revenue → EPS ~$5.0–5.8; the market re-rates a re-proven franchise toward ~3x sales / ~22–24x EPS → ~$110–135 (back toward, though still below, the old highs). This requires proof that the moat is restored, not just a cyclical bounce.

Sum-of-the-parts sanity check. The crown-jewel brands (La Mer, Estée Lauder, the luxury-fragrance stable) on a standalone basis would command premium multiples; the weaker assets (Too Faced, Dr.Jart+, parts of makeup) carry negative option value (further impairment). The ~$40bn enterprise value Puig reportedly contemplated for a combined entity is not a clean read-through, but it signals strategic acquirers see real value in the portfolio near current levels — a soft floor.

Verdict: EL is cheap on its own history but only fairly valued on a realistic normalized margin. The valuation already embeds the guided recovery; the upside requires the recovery to exceed guidance and the multiple to re-rate, which is a genuine but unproven possibility. There is no margin of safety in the asset (negative tangible book); the margin of safety, such as it is, comes only from the depressed earnings base and the takeover-interest floor.

11. Variant Perception

Consensus view. Sell-side is cautious-constructive — recently exemplified by Bernstein initiating at Market Perform (June 2026). The consensus narrative: a quality franchise in a credible-but-early turnaround; respect the margin progress and China share gains, but the stock has already doubled off the lows, the recovery is guided (so partly priced), and visibility on the terminal margin/growth is low. “Show me more before paying up.”

The strongest bull case. EL is a genuine wide-moat-caliber asset (74% gross margins don’t lie) at the cheapest valuation in a decade, with (a) a self-help margin recovery that has control over its own destiny — $0.8–1.0B of identified cost savings driving +500bps of margin (8%→13%) over two years independent of the macro; (b) a real demand inflection (China five straight quarters of share gain, Hainan +30%, fragrance double-digit, U.S. volume-share gains across all four categories); © huge operating leverage off a trough Asia/Pacific profit pool ($9M vs $824M prior); and (d) a takeover-interest floor (Puig). If margins normalize to the mid-teens and the multiple re-rates even partway back toward history, the stock doubles.

The strongest bear case. EL’s moat was narrower and more channel-dependent than believed; the FY21–22 boom was a bubble that won’t repeat; department stores are in permanent decline; makeup share is structurally lost to indies; China is permanently more competitive and lower-margin; and the company has proven it overpays for M&A (three impairments). On this view, the normalized margin is ~12–13% (not the old 18–20%), ROIC settles in the low teens, growth is a pedestrian low-single-digit, and ~2x sales is fair value, not a discount — the stock is a value-trap that re-rated too far on hope. The zero insider buying at the trough is the bear’s exhibit A.

The 3–5 assumptions that matter most:

1. Terminal operating margin — mid-teens-plus (bull) vs. ~12–13% plateau (bear). This is the whole debate.
2. China + travel-retail durability — structural recovery vs. dead-cat bounce off destocking.
3. Makeup/competitive trajectory — can EL stop the share bleed and re-engage Gen-Z via Sephora/TikTok/Amazon, or is the category permanently lost?
4. Channel transition economics — does shifting from department stores to online/specialty-multi preserve margin, or is the new mix structurally lower-margin?
5. No further large impairment (TOM FORD $1.8B residual).

Falsification. Bull thesis breaks if FY27 margin guidance is cut or organic growth rolls back to flat/negative, or if China/travel-retail relapse — proving the recovery was cyclical, not structural. Bear thesis breaks if EL sustains mid-single-digit organic growth with operating margin durably through 13% toward the mid-teens for several quarters, with broad category/region participation — proving the franchise is being genuinely restored.

Factor-positioning read (where consensus may be offsides). The factor model frames EL as a high-beta (~1.33–1.58), strongly negative-momentum (−0.65 loading) fallen-angel with a Consumer-Staples sector tilt and a small China/Hong-Kong loading. Its risk-adjusted track record is grim on the long horizons (5-year −21%/yr, max drawdown −86%) but positive on 1 year (+15%) and negative again over the last 6 months (−34% annualized) — i.e., a violently volatile name that bounced hard off the trough and then rolled over, not a clean uptrend and not a clean falling knife. Its closest factor twin is Coty — the other broken prestige-beauty name. The read: this is a contested, low-conviction, high-volatility situation where positioning is neither washed-out-capitulation (the bounce already happened) nor crowded-long (negative momentum, cautious sell-side). That argues for patience and weakness-buying rather than chasing — consistent with the Author’s Take.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the true normalized operating margin? Management implies a path to mid-teens-plus over time, but offers only 12.5–13% for FY27. The terminal margin is the single biggest unknown and the entire valuation pivots on it.
2. Is the China/travel-retail recovery structural or a destocking bounce? Five quarters of share gains is encouraging, but China consumer sentiment is “still subdued” and the comparison base is depressed.
3. Channel mix economics. EL does not disclose channel-level revenue or A&P spend. As the mix shifts from department stores to online/specialty-multi/Amazon/TikTok Shop, is the margin preserved? (Online and marketplace channels can carry higher customer-acquisition cost and platform fees.)
4. TOM FORD’s $1.8B residual trademark — at an 11.5% WACC against a still-soft fragrance/makeup brand, is another impairment coming?
5. Brand concentration — EL discloses no brand-level revenue. How dependent is the portfolio on La Mer + Estée Lauder + the top handful of brands, and how exposed is it if any crown jewel falters?
6. A&P intensity — historically ~25%+ of sales but undisclosed. Is the margin recovery partly being funded by under-investing in brand support, which would borrow from future growth?
7. Family succession / control intentions — post-Leonard Lauder, with a generational transition underway, will the family remain a permanently entrenched standalone owner, or could a future combination (Puig-style) resurface?

14. What Must Be True

Bull case — what must be true (and its falsification test):

• EL’s brands retain durable pricing power and the gross margin stays ~74%+ → Falsified if gross margin erodes below ~72% on channel-mix shift or promotional pressure.
• PRGP delivers $0.8–1.0B of recurring savings and operating margin marches through 13% toward the mid-teens → Falsified if FY27 margin guidance (12.5–13%) is cut or margin plateaus below 13% for several quarters.
• China + travel retail durably grow, and the Americas/EUKEM stabilize-to-grow → Falsified if China/travel-retail roll back to negative organic growth.
• Makeup share loss halts and reverses via the new channels (Sephora/Amazon/TikTok) → Falsified if makeup continues losing value share despite the re-platforming.
• Single cleanest bull trigger: two-to-three consecutive quarters of mid-single-digit organic growth with operating margin visibly above 13% and rising, broadly across categories and regions.

Bear case — what must be true (and its falsification test):

• The FY21–22 boom was a non-repeatable bubble and normalized margin is structurally ~12–13%, not the old high-teens → Falsified if margin durably exceeds 14–15%.
• Department-store decline and indie competition permanently lower EL’s growth and mix → Falsified if EL sustains share gains across categories and channels for a year-plus.
• ~2x sales is fair value, not a discount → Falsified if the market re-rates toward 3x sales on proven margin normalization.
• Single cleanest bear trigger: a cut to FY27 margin/growth guidance, a China/travel-retail relapse, or another TOM FORD-scale impairment — any of which says the franchise is permanently lower-quality.

15. Source Appendix

(See the separate Source Appendix file for the full citation list. Primary sources: EL FY2023–FY2025 Forms 10-K and FY2026 Forms 10-Q (SEC EDGAR CIK 0001001250); EL DEF 14A proxies (2024, 2025); EL FY2026 Q3 earnings call transcript (May 1, 2026) and press releases; EL/Puig press releases (Mar 23, 2026; May 21, 2026); aggregated public financials/ratios; five-year public price history and own-history valuation percentiles; a public factor model; company news; CNBC and trade-press coverage of the Puig discussions.)

APPENDIX A — Standard Diligence Questionnaire

The Estée Lauder Companies Inc. (NYSE: EL) — as of 2026-06-20

Supplemental diligence record. Fact/Interpretation/Assumption labels applied where material.

General

What thoughtful questions have other investors asked about this company?

• Is the COVID-era China/travel-retail demand permanently impaired, or is the FY23–25 collapse a destocking cycle that recovers? (The central debate.)
• What is EL’s true normalized operating margin now — mid-teens-plus (recoverable) or ~12–13% (structurally lower)?
• Has EL permanently lost the makeup category to indie/Gen-Z brands, and can the crown-jewel skin-care/fragrance brands carry the franchise?
• Why did EL serially overpay for acquisitions (TOM FORD, Too Faced, Dr.Jart+ all impaired), and is the M&A discipline now genuinely different?
• Does Lauder-family control (~84% of votes) entrench underperformance or provide long-term stability — and what does the failed Puig deal signal?
• Was the dividend cut the bottom, or a sign of deeper trouble?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? A cyclical/idiosyncratic LOW (Fact). FY25 was a net loss (−$1.13B) on an 8% operating margin vs a 20% peak; ROIC went negative. Earnings are depressed by impairments, restructuring, deleverage, and the China/travel-retail air-pocket. FY26 is the recovery’s first year.

Driven by the external environment or internal actions? Both (Interpretation). External: China consumer weakness, travel-retail/Hainan reseller normalization, department-store decline, tariffs, Middle East conflict. Internal: over-reliance on the boom channels, ill-timed M&A, an over-stretched cost base — now being addressed by PRGP/Beauty Reimagined.

How stable are revenues? Less stable than a typical staple (Fact). The consumer demand for beauty consumables is reasonably stable, but EL’s reported revenue is highly sensitive to a few volatile channels/geographies (China, travel retail, department stores) — hence a $17.7B→$14.3B swing.

Outlook for products/services? Category is structurally growing (premiumization, emerging-market middle class, widening age range). EL guides FY26 ~3% organic, FY27 3–5%. Fragrance strongest; skin care recovering; makeup decline slowing.

How big will this market be? Global beauty ~$500B+ and growing low-to-mid-single digits secularly, with prestige growing faster; international and emerging-market skewed (EL >70% ex-US). Growing, global.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More (Interpretation). Indie/Gen-Z brands, China “C-beauty,” retailer private label, and channel disruption (department-store decline, platform power) have all raised intensity.

How profitable is the business (ROIC, ROE)? Was high-quality (ROIC ~19–25% FY19–22), now sub-WACC (negative FY25); ROE collapsed similarly. Recovery thesis = ROIC back to low-teens-plus. Gross margin ~74% intact.

How profitable is the industry / barriers to entry? Category profit pools are rich (prestige gross margins 70%+), but barriers to entry have fallen in makeup (contract manufacturing + social distribution); barriers remain higher in luxury skin care and fragrance (brand heritage, formulation). Brands matter enormously — but brand loyalty is to individual brands, not to EL.

Can the business be easily understood? Yes — a prestige-beauty brand portfolio sold globally through wholesale + DTC.

Can it be undermined by foreign low-cost labor? Not directly (premium brand value, not cost-based) — but it can be undermined by lower-cost/faster indie and local-market competitors.

Do brands matter? Critically — they are the entire moat. La Mer, Estée Lauder, Clinique, M·A·C, Jo Malone, TOM FORD, Le Labo, The Ordinary.

Nature of competition / switching costs. Competition on brand desirability, innovation, channel presence, and marketing. Consumer switching costs are low (no lock-in) — EL relies on brand affinity and habit, not captivity.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the brand equity of the crown-jewel brands (internally built brands like Estée Lauder/Clinique/La Mer carry little/no balance-sheet value) is worth far more than booked. (Interpretation.)

Off-balance-sheet liabilities? Operating/lease commitments (capitalized), talc-litigation tail (partly reserved via $159M FY25 settlement framework through 2029), standard purchase obligations. Nothing unusual.

How conservative is the accounting? Reasonably conservative QoE (Fact) — the FY25 GAAP loss is worse than cash earnings because of non-cash impairments; OCF was positive ($1.27B). EL has, if anything, taken impairments aggressively (three brands written down). Watch TOM FORD’s $1.8B residual.

How CapEx-hungry? Low-to-moderate — capex was being cut (FY26 9-mo $306M, −23%); not capital-intensive. The “investment” is in A&P and brand-building (expensed), not fixed assets.

Capital Allocation & Management

FCF generation and use / philosophy. Generates positive OCF (~$1.2–1.3B even in the trough). Current use: deleveraging, PRGP, reinvestment, reduced dividend, minimal buyback, small tuck-ins. Philosophy has shifted from peak-cycle M&A-and-buyback to cost-discipline-and-preservation. (Improved.)

Significant acquisitions recently? Only tuck-ins now (Forest Essentials buy-out, 111Skin minority). The prior big deals — TOM FORD (2023), Dr.Jart+ (2019), Too Faced (2016) — are all impaired. (Poor historical record.)

Buying back shares? Halted (FY24–25 ~$35M vs $2.3B FY22). Prior buybacks were pro-cyclical (bought high). Halting in the trough was correct for liquidity.

Issuing shares to insiders? SBC ~$304M/yr (~2% of sales), moderate; share count roughly flat (~360M).

Compensation policy. Bonus (FY26) = Net Sales 20 / EPS 20 / Op Margin 20 / ROIC 20 / Strategic 20; PSU = Net Sales 40 / EPS 40 / ROIC 20. Uses ROIC and per-share EPS (above-average); no relative-TSR, no FCF metric. CEO FY25 comp $21.8M (rich for a loss year, mostly recovery-contingent equity). Say-on-pay ~93%.

Motivations of management. New CEO (de La Faverie, 14-yr insider) and CFO incentivized on margin/ROIC/EPS recovery. Lauder family (~84% votes) motivated by long-term franchise stewardship and dividend income — and by not ceding control (Puig rejected).

Valuation & Market Data

ADR / MLP / K-1? No — U.S. C-corp, NYSE-listed Class A common; standard 1099. Dual-class (Class B 10-vote, family-held).

Dividend policy. Cut ~47% ($0.66→$0.35/qtr) from Oct-2024 — first reduction in modern company history; held at $0.35 since. Trailing yield ~1.6%. (Capital preservation.)

How profitable is the business? Currently trough (8% op margin, negative ROIC FY25); historically high-quality (20% peak op margin, ~19–25% ROIC). Gross margin ~74% intact.

Net income vs cash from operations diverging? Yes, favorably — FY25 GAAP net loss −$1.13B vs positive OCF $1.27B (gap = non-cash impairments/deferred tax). Cash generation is healthier than GAAP earnings.

Risks & Downside

What would cause the stock to decline? Margin recovery stalling ~11–12%; China/travel-retail relapse; resumed makeup/skin-care share loss; another impairment (TOM FORD); cut to FY27 guidance; ratings downgrade; tariff/geopolitical escalation.

Risk of catastrophic loss? Low (Interpretation) — positive OCF, investment-grade balance sheet, undrawn $3.5B revolver, real brand value, takeover-interest floor. The realistic bad case is a value-trap de-rating, not insolvency.

Chance of total loss? Very low. Note the equity has no tangible asset floor (tangible book ~−$2B), so the value rests entirely on franchise earning power — but solvency is not at risk.

Recent News & Events

Has the business environment changed recently? Yes — FY26 inflection to growth + margin expansion; China five straight quarters of share gain; Hainan +30%; fragrance double-digit. Headwinds: tariffs, Middle East conflict, U.S. retailer bankruptcies.

Significant acquisitions / change in accounting? No major M&A (Puig ~$40bn combination discussed Mar-2026, terminated May-2026). New FY26 four-region segment structure (isolating China and travel retail) — a transparency improvement, not an accounting-quality change.

Recent changes — markets, facilities, management? New CEO (de La Faverie, Jan-2025) and CFO (Shrivastava); William Lauder non-exec Chair; Leonard Lauder died Jun-2025; Ronald Lauder off board. “One ELC” reorg; PRGP restructuring doubled ($1.5–1.7B); major vendor partnerships (Accenture/Shopify/WPP); channel pivot to online/specialty-multi/Amazon/TikTok Shop; M·A·C into U.S. Sephora.

APPENDIX B — Source Appendix

The Estée Lauder Companies Inc. (NYSE: EL) — Research as of 2026-06-20

Primary sources prioritized. SEC filings via EDGAR (CIK 0001001250). Aggregated public data reconciled to filings; treated as starting points, not authority.

Primary — SEC Filings (EDGAR CIK 0001001250)

1. Form 10-K FY2025 (fiscal year ended June 30, 2025), filed 2025-08-20 — segment/category & geographic revenue and operating income; impairments (TOM FORD $773M, Too Faced $138M, Dr.Jart+ $375M); PRGP scope/charges/headcount; risk factors; competition; R&D ($316M); dividend-cut disclosure; credit ratings (A−/A3 negative); talc settlement ($159M); liquidity.
2. Form 10-K FY2024, filed 2024-08-19 — trend/prior-year comparatives; Dr.Jart+ FY24 impairment ($471M).
3. Form 10-K FY2023, filed 2023-08-18 — peak-to-decline comparatives.
4. Forms 10-Q FY2026 (Q1 ended 2025-09-30; Q2 ended 2025-12-31; Q3 ended 2026-03-31) — quarterly revenue/margin trajectory; PRGP charge updates.
5. DEF 14A Proxy 2025 (filed 2025-09-25) — Lauder family dual-class control (~84% votes / ~35% economics); board composition; CEO transition; executive comp metrics (ROIC 20% / EPS / Net Sales / Op Margin); CEO comp ($21.8M FY25); say-on-pay (~93%).
6. DEF 14A Proxy 2024 (filed 2024-09-19) — prior comp/governance comparatives.
7. Forms 4 (insider transactions, ~50-filing sample April 2025–June 2026) — zero open-market purchases; routine grants/exercises/tax-withholding; estate-driven family-trust sales (Leonard A. Lauder 2013 Trust ~2.79M sh @ ~$89.70). EDGAR CIK 1001250; index at
8. 8-K material events (FY2024–FY2026) — dividend reduction; CEO transition; PRGP announcements/expansion; quarterly earnings releases.

Primary — Company Disclosures & Transcripts

9. EL FY2026 Q3 earnings call transcript (May 1, 2026) — FY26 raised guidance (organic ~3%, op margin 10.7–11%, adj EPS $2.35–2.45); FY27 preliminary (3–5% sales, 12.5–13% margin); China share gains; Hainan +30%; PRGP charges $1.5–1.7B; 9-mo OCF $1.2B. Source: company earnings-call transcript / investor relations.
10. EL/Puig press release — “End Discussions Regarding a Potential Business Combination” (May 21, 2026), elcompanies.com newsroom.
11. EL statement on potential transaction with Puig (March 23, 2026), company press release / BusinessWire.
12. EL — “to acquire the TOM FORD brand” (Nov 15, 2022), company press release / BusinessWire (acquisition-price context for the later impairment).

Secondary — Market & Industry

13. CNBC — “Estée Lauder surges in premarket after Puig merger deal talks end” (May 22, 2026).
14. Business Chief — “How Estée Lauder and Puig Could Create a $40bn Beauty Giant” (2026) — deal-scale context.
15. NPR — “Estée Lauder buys Tom Ford Beauty” (Nov 15, 2022).
16. Bernstein — initiation at Market Perform (June 12, 2026), per company news feed.

Quantitative Data (reconciled to filings)

• Company financial statements, ratios (ROIC/ROE/margins), enterprise value and valuation multiples (FY2019–FY2025 annual; FY2025–FY2026 quarterly) and the latest earnings-call transcript, from public filings and aggregated public data.
• Five-year daily price/OHLCV history (split/dividend-adjusted) and own-history valuation percentile ranks (P/S ~10th, P/B ~21st, composite ~16th) from public market data.
• Factor model: loadings (Momentum −0.65, Market ~1.42, Consumer Staples ~0.48), risk-adjusted returns by horizon (max drawdown −86%), beta 1.33, and factor-similar peers (twin: COTY), from public factor data.

Notes on Authority

• For all US-GAAP figures, the 10-K/10-Q is primary; aggregated public figures were used only to accelerate and cross-check, and were reconciled to the filings.
• Management commentary (transcript/guidance) is treated as hypothesis, validated against filings and external evidence .
• No price target or BUY/SELL appears in the analytical body; the single labeled opinion is a personal view only.